Financial Daily from THE HINDU group of publications
Friday, Oct 22, 2004

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Money & Banking - Financial Services


Rabo India to advise Sterling Biotech on overseas buy

Our Bureau

Mumbai , Oct. 21

RABO India Finance has been appointed as a sole advisor to Sterling Biotech Ltd to identify and arrange for overseas acquisition opportunities in the European market.

In addition, Rabo India Finance has also extended a Rs 40-crore long-term funding facility to Sterling Biotech, a news release from Rabo India Finance said.

According to Mr Sanjiv Bhasin, CEO, Rabo India, said "We will be working with the research team of a leading German bank specialising in distinct niche and emerging sectors including life sciences and biotechnology to identify the best opportunities for Sterling Biotech. " .

Rabo India Finance has inked a strategic alliance with this German bank to tap the growing cross border mergers and acquisitions activity between life sciences companies of both these countries.

More Stories on : Financial Services | Bio-tech & Genetics

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Rabo India to advise Sterling Biotech on overseas buy


Rupee tad higher; bond prices rally
HDFC Bank Q2 net up 30 pc — Board approves $300-m ADS plan
Treasury gains dented; ICICI Bank Q2 net rises 10 pc
Corpn Bank Q2 net down 81 pc
Draft code of conduct for NBFCs ready
NBFC registration annulled
ICICI Pru Life new premium up 169 pc
Syndicate Bank launches new products
Vijaya Bank Founders' Day
Banks step up NPA recovery efforts
Study analyses poor credit-deposit ratio in Kerala
Keep interest rates in line with market trends, RBI tells UCBs



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line